Oncternal Therapeutics Stock Price To Book
| ONCT Stock | USD 8.60 0.06 0.69% |
Oncternal Therapeutics fundamentals help investors to digest information that contributes to Oncternal Therapeutics' financial success or failures. It also enables traders to predict the movement of Oncternal Stock. The fundamental analysis module provides a way to measure Oncternal Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oncternal Therapeutics stock.
Price To Book Ratio is likely to drop to 1.00 in 2024. Oncternal | Price To Book |
Oncternal Therapeutics Company Price To Book Analysis
Oncternal Therapeutics' Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current Oncternal Therapeutics Price To Book | 0.93 X |
Most of Oncternal Therapeutics' fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oncternal Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Oncternal Price To Book Driver Correlations
Understanding the fundamental principles of building solid financial models for Oncternal Therapeutics is extremely important. It helps to project a fair market value of Oncternal Stock properly, considering its historical fundamentals such as Price To Book. Since Oncternal Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Oncternal Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Oncternal Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
Oncternal Book Value Per Share
Book Value Per Share |
|
Based on the latest financial disclosure, Oncternal Therapeutics has a Price To Book of 0.9258 times. This is 96.39% lower than that of the Biotechnology sector and 84.67% lower than that of the Health Care industry. The price to book for all United States stocks is 90.26% higher than that of the company.
Oncternal Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oncternal Therapeutics' direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oncternal Therapeutics could also be used in its relative valuation, which is a method of valuing Oncternal Therapeutics by comparing valuation metrics of similar companies.Oncternal Therapeutics is currently under evaluation in price to book category among related companies.
Oncternal Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Oncternal Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Oncternal Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Oncternal Fundamentals
| Return On Equity | -0.87 | ||||
| Return On Asset | -0.49 | ||||
| Operating Margin | (15.43) % | ||||
| Current Valuation | (8.31 M) | ||||
| Shares Outstanding | 2.96 M | ||||
| Shares Owned By Insiders | 9.23 % | ||||
| Shares Owned By Institutions | 15.57 % | ||||
| Number Of Shares Shorted | 12.95 K | ||||
| Price To Earning | (37.77) X | ||||
| Price To Book | 0.93 X | ||||
| Price To Sales | 35.44 X | ||||
| Revenue | 785 K | ||||
| Gross Profit | (31.49 M) | ||||
| EBITDA | (41.71 M) | ||||
| Net Income | (39.48 M) | ||||
| Cash And Equivalents | 78.9 M | ||||
| Cash Per Share | 1.48 X | ||||
| Total Debt | 318 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 10.78 X | ||||
| Book Value Per Share | 10.19 X | ||||
| Cash Flow From Operations | (32.16 M) | ||||
| Short Ratio | 2.11 X | ||||
| Earnings Per Share | (12.33) X | ||||
| Target Price | 27.67 | ||||
| Number Of Employees | 27 | ||||
| Beta | 1.36 | ||||
| Market Capitalization | 25.63 M | ||||
| Total Asset | 36.73 M | ||||
| Retained Earnings | (197.78 M) | ||||
| Working Capital | 30.86 M | ||||
| Current Asset | 27.27 M | ||||
| Current Liabilities | 6.3 M | ||||
| Net Asset | 36.73 M |
About Oncternal Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oncternal Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncternal Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncternal Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Oncternal Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Oncternal Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Oncternal Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Oncternal Therapeutics Stock: Check out Oncternal Therapeutics Piotroski F Score and Oncternal Therapeutics Altman Z Score analysis. For more information on how to buy Oncternal Stock please use our How to Invest in Oncternal Therapeutics guide.Note that the Oncternal Therapeutics information on this page should be used as a complementary analysis to other Oncternal Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for Oncternal Stock analysis
When running Oncternal Therapeutics' price analysis, check to measure Oncternal Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncternal Therapeutics is operating at the current time. Most of Oncternal Therapeutics' value examination focuses on studying past and present price action to predict the probability of Oncternal Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncternal Therapeutics' price. Additionally, you may evaluate how the addition of Oncternal Therapeutics to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Oncternal Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncternal Therapeutics. If investors know Oncternal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncternal Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (12.33) | Revenue Per Share 0.39 | Quarterly Revenue Growth 1.803 | Return On Assets (0.49) | Return On Equity (0.87) |
The market value of Oncternal Therapeutics is measured differently than its book value, which is the value of Oncternal that is recorded on the company's balance sheet. Investors also form their own opinion of Oncternal Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Oncternal Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncternal Therapeutics' market value can be influenced by many factors that don't directly affect Oncternal Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncternal Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncternal Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncternal Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.